
FÃ;tima V Ventura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5123756/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods. Nanomaterials, 2020, 10, 455.	4.1	55
2	Unveiling the Pathogenic Molecular Mechanisms of the Most Common Variant (p.K329E) in Medium-Chain Acyl-CoA Dehydrogenase Deficiency by <i>in Vitro</i> and <i>in Silico</i> Approaches. Biochemistry, 2016, 55, 7086-7098.	2.5	5
3	Insights into Mediumâ€chain Acylâ€CoA Dehydrogenase Structure by Molecular Dynamics Simulations. Chemical Biology and Drug Design, 2016, 88, 281-292.	3.2	9
4	The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders. Annual Review of Physiology, 2016, 78, 23-44.	13.1	490
5	Retrospective study of the mediumâ€chain acylâ€ <scp>CoA</scp> dehydrogenase deficiency in Portugal. Clinical Genetics, 2014, 85, 555-561.	2.0	11
6	Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1467-1474.	2.4	74
7	Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines. FASEB Journal, 2013, 27, 2039-2044.	0.5	58
8	Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched-chain amino acid metabolism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 773-779.	3.8	69
9	Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 728-732.	3.8	37
10	Inhibition of adenine nucleotide transport in rat liver mitochondria by long-chain acyl-coenzyme A β-oxidation intermediates. Biochemical and Biophysical Research Communications, 2007, 352, 873-878.	2.1	14
11	Differential inhibitory effect of long-chain acyl-CoA esters on succinate and glutamate transport into rat liver mitochondria and its possible implications for long-chain fatty acid oxidation defects. Molecular Genetics and Metabolism, 2005, 86, 344-352.	1.1	34
12	Quantitative acylcarnitine profiling in fibroblasts using [U-13C] palmitic acid: an improved tool for the diagnosis of fatty acid oxidation defects. Clinica Chimica Acta, 1999, 281, 1-17.	1.1	79
13	Lactic acidosis in long-chain fatty acid β-oxidation disorders. Journal of Inherited Metabolic Disease, 1998, 21, 645-654.	3.6	31
14	Carnitine palmitoyltransferase II specificity towards beta-oxidation intermediates. Evidence for a reverse carnitine cycle in mitochondria. FEBS Journal, 1998, 253, 614-618.	0.2	30
15	Broad specificity of carnitine palmitoyltransferase II towards long-chain acyl-CoA β-oxidation intermediates and its practical approach to the synthesis of various long-chain acylcarnitines. Journal of Inherited Metabolic Disease, 1997, 20, 423-426.	3.6	5
16	Inhibitory effect of 3-hydroxyacyl-CoAs and other long-chain fatty acidβ-oxidation intermediates on mitochondrial oxidative phosphorylation. Journal of Inherited Metabolic Disease, 1996, 19, 161-164.	3.6	40
17	Inhibition of oxidative phosphorylation by palmitoyl-CoA in digitonin permeabilized fibroblasts: implications for long-chain fatty acid β-oxidation disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1995, 1272, 14-20.	3.8	40